INIPARIB: 36 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
36
Total FAERS Reports
4 (11.1%)
Deaths Reported
17
Hospitalizations
36
As Primary/Secondary Suspect
First Report: 2008 · Latest Report: 201503
What Are the Most Common INIPARIB Side Effects?
#1 Most Reported
Thrombocytopenia
16 reports (44.4%)
#2 Most Reported
Anaemia
16 reports (44.4%)
#3 Most Reported
Malignant neoplasm progression
15 reports (41.7%)
All INIPARIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Anaemia | 16 | 44.4% | 0 | 16 |
| Thrombocytopenia | 16 | 44.4% | 0 | 16 |
| Malignant neoplasm progression | 15 | 41.7% | 0 | 15 |
| Disease progression | 10 | 27.8% | 0 | 10 |
| Invasive ductal breast carcinoma | 10 | 27.8% | 0 | 10 |
| Metastases to bone marrow | 10 | 27.8% | 0 | 10 |
| Product use in unapproved indication | 10 | 27.8% | 0 | 10 |
| Bone marrow infiltration | 6 | 16.7% | 0 | 6 |
Who Reports INIPARIB Side Effects? Age & Gender Data
Gender: 100.0% female, 0.0% male. Average age: 53.7 years. Most reports from: GR. View detailed demographics →
Is INIPARIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2008 | 13 | 0 | 13 |
| 2015 | 3 | 0 | 3 |
What Is INIPARIB Used For?
| Indication | Reports |
|---|---|
| Invasive ductal breast carcinoma | 15 |
| Metastases to bone | 13 |
| Breast cancer | 8 |
Official FDA Label for INIPARIB
Official prescribing information from the FDA-approved drug label.